Simulations Plus (NASDAQ:SLP) Updates FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.070-1.200 for the period. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $91.8 million. Simulations Plus also updated its FY25 guidance to $1.07 to $1.20 EPS.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. JMP Securities assumed coverage on shares of Simulations Plus in a report on Tuesday, July 16th. They set a “market perform” rating on the stock. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Thursday, September 12th. Craig Hallum reiterated a “buy” rating and set a $56.00 target price on shares of Simulations Plus in a report on Wednesday, July 3rd. Finally, KeyCorp assumed coverage on shares of Simulations Plus in a report on Monday, July 29th. They set an “overweight” rating and a $47.00 target price on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Simulations Plus Trading Down 0.8 %

Shares of NASDAQ SLP traded down $0.27 during mid-day trading on Wednesday, reaching $33.98. The company had a trading volume of 399,370 shares, compared to its average volume of 126,490. The firm has a 50 day simple moving average of $33.35 and a two-hundred day simple moving average of $40.87. The stock has a market cap of $679.94 million, a P/E ratio of 71.35 and a beta of 0.69. Simulations Plus has a 52-week low of $29.37 and a 52-week high of $51.22.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total transaction of $703,600.00. Following the transaction, the director now directly owns 3,501,592 shares of the company’s stock, valued at approximately $123,186,006.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders have sold 60,750 shares of company stock valued at $2,145,055. Insiders own 20.90% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.